WO2000027466A1 - Electrically mediated angiogenesis - Google Patents
Electrically mediated angiogenesis Download PDFInfo
- Publication number
- WO2000027466A1 WO2000027466A1 PCT/US1999/026834 US9926834W WO0027466A1 WO 2000027466 A1 WO2000027466 A1 WO 2000027466A1 US 9926834 W US9926834 W US 9926834W WO 0027466 A1 WO0027466 A1 WO 0027466A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- targeted body
- body tissue
- electrical
- electrodes
- electrical field
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/205—Applying electric currents by contact electrodes continuous direct currents for promoting a biological process
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
- A61N1/303—Constructional details
- A61N1/306—Arrangements where at least part of the apparatus is introduced into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/326—Applying electric currents by contact electrodes alternating or intermittent currents for promoting growth of cells, e.g. bone cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
- A61N1/36017—External stimulators, e.g. with patch electrodes with leads or electrodes penetrating the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
- A61N1/3603—Control systems
- A61N1/36034—Control systems specified by the stimulation parameters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/3627—Heart stimulators for treating a mechanical deficiency of the heart, e.g. congestive heart failure or cardiomyopathy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/365—Heart stimulators controlled by a physiological parameter, e.g. heart potential
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/3629—Heart stimulators in combination with non-electric therapy
Definitions
- the present application relates to angiogenesis, and more particularly to the
- angiogenesis There are believed to be two main types of vascular disease which are especially suitable for treatment by angiogenesis therapy, namely coronary artery disease and
- peripheral vascular disease peripheral vascular disease.
- Coronary artery disease is a disease that restricts the flow of blood to the myocardial
- the blockages can cause an
- Ischemia in the heart is generally present in those with coronary vessel
- Peripheral vascular disease is indicated when blood flow is restricted to areas other
- ischemic areas are often induced by vascular blood clots or
- the ischemic limb often occurs in
- angiogenesis the process of creating or generating new blood vessels.
- One method to promote angiogenesis is by direct injection of an angiogenic agent .
- transfection efficiency of such local such delivery by direct injection is generally believed to be about 1% to 2%.
- Another method of direct injection employs electroporation, or a treatment of tissue with a series of high-energy electrical pulses to porate the tissue and allow the genetic
- angiogenesis while avoiding the need for any introduction of foreign agents.
- control mechanism interconnected with the power supply; and a plurality of electrodes designed
- the plurality of electrodes are in
- control mechanism controls an amplitude and a duration of a period of delivery of electrical pulse from the power supply to the
- the duration of the period of delivery is sufficient to stimulate angiogenesis in the targeted body tissue; preferably by causing living cells within the
- VEGF vascular endothelial growth factor
- the electrical field generating unit is a
- the delivery device The amplitude of the electrical current delivered to the targeted body tissue by
- the constant current delivery device is preferably from about OJmA to about 250mA and the
- the electrical field generating unit is a
- the delivery device The amplitude of the electrical voltage delivered to the targeted body tissue by
- the constant voltage delivery device is preferably a generally constant voltage of from about
- the electrical field is produced by
- a number of pulses in the range of from 1 to about 1000 pulses with a frequency between about
- the electrical field is preferably generated for a duration between about
- control mechanism includes a computer processing unit in electronic communication with the power supply, the computer processing unit being
- the plurality of electrodes are configured in a manner selected from the group consisting of unipolar, bipolar, and multiple electrode
- the apparatus is preferably designed and configured to be implantable.
- the present invention also includes a method of treatment of targeted body tissues by:
- angiogenesis can be any organic compound having a wide range of properties.
- angiogenesis can be any organic compound having a wide range of properties.
- the procedure provides minimum discomfort and may
- the main power supply can be reused, while the
- Electrodes are disposable.
- Another advantage is that the present invention can be used to treat deep tissues, as
- Certain techniques may be either invasive, minimally invasive, or noninvasive. Furthermore, the treatment of the ischemic tissue can be targeted while
- Figure 2A schematically illustrates an electrical stimulation apparatus for generating
- Figure 2B is an enlarged broken away side view of a portion of electrical stimulation
- FIG. 3 schematically illustrates an alternative embodiment of the electrical
- Figure 4A illustrates an alternate electrical stimulation apparatus having a single
- Figure 4B is an enlarged broken away side view of a portion of the electrical
- FIG. 5 schematically illustrates an alternative application of the apparatus shown in
- FIG. 6 schematically illustrates an alternative application of the electrical
- FIG. 7 schematically illustrates another alternative application of the electrical
- Figure 8 A schematically illustrates an alternative embodiment of an application of an
- alternate electrical stimulation device having two electrodes, both of which are patch-type
- Figure 8B is a perspective view of the contact surface of the alternate patch-type
- electrode 130 shown in Figure 8 A having a plurality of pins which can insert into the body
- Figure 8C is a perspective view of an alternate patch-type electrode 142 having a
- FIGS. 9A-9B schematically illustrate an alternative embodiment of the electrical
- Figure 10 schematically illustrates an alternate application of a further embodiment of the electrical stimulation apparatus of the present invention.
- FIGS 11 A-l ID schematically illustrate circuits which are representative of alternate circuits which can be employed when certain of the alternate electrical stimulation apparatti of the present invention are employed to deliver an electrical field to various targeted body
- the present invention relates to an apparatus for generating an electrical
- targeted body tissue which located in an electrical path between at least two electrodes of
- Such delivery is believed to promote a cell-initiated angiogenic response
- the cell-initiated angiogenic response is believed to include a cellular
- Figures lA-lC electrically-mediated angiogenesis is illustrated in Figures lA-lC.
- Figure 1A illustrates an array of epithelial cells 4 in culture distributed in a normal growth pattern before the
- Figure IB illustrates the beginning stages of angiogenesis
- Figure IC illustrates what is believed to be the initial formation of the tube structures 6 in such cell
- FIGS. 2A and 2B schematically illustrate an electrical stimulation apparatus 10 of
- the present invention useful for stimulation of ischemic tissue and other targeted body tissues
- the apparatus 10 includes a needle 100
- the distal portion 110 includes an
- electrically conductive shaft 102 which forms a primary electrode, an insulating material 104
- the shaft 102 has a
- the diameter of the proximal portion 112 is
- a radially oriented surface 114 defines a distal end of the proximal portion 1 12 and forms a depth guide 1 14 that generally limits the
- the proximal end 112 of the needle 100 can be inserted into the patient's body
- the distance between the distal tip 108 of the needle 100 and the depth guide 1 14 can be any distance between the distal tip 108 of the needle 100 and the depth guide 1 14 .
- the needle 100 also defines a lumen 1 15 and defines delivery ports 1 16 in the distal
- the lumen 115 and delivery ports 116 enable injection of a liquid into the
- targeted body tissues including agents such as an angiogenic agents and/or cooling mediums
- the needle 100' is solid and does not include delivery ports, so that
- the needle 100 is in electrical communication via
- EFGU electrical field generating unit
- control mechanism 1 19 is a computer processing unit which is programmed to generate a preferred electrical field within a proximate to a targeted body tissue.
- 117' will include an electrical power supply 117a, a switch 117b and a variable resistor so that
- the current may be varried and the circuit can be broken.
- the EFGU the current may be varried and the circuit can be broken.
- 117 is a constant current delivery device, such as an iotophoretic electrical current generation
- CCDD constant current delivery device
- dose controller In order to effectively provide computer controls for the CCDDs, appropriate modifications are made to provide for programmed control of these devices by a
- EFGU 117 is a constant voltage delivery device (CVDD), then a device similar to the PA-4000 sold by CYTOPULSE, Inc. will be used.
- CVDD constant voltage delivery device
- a flexible, patch-type electrode 120 is also in electrical
- additional needle can be used in place of the patch-type electrode 120 or, converesely, an
- patch additional patch-type electrode (hereinafter patch) can be used in place of the needle 100.
- the source of current 117 will generally include a signal generator, a variable resistor, a
- the source of current 117 is controlled by a microprocessor or other computer processing unit (CPU) 1 19 which is preferably programmed to cause the electrical stimulation apparatus to deliver a predetermined amount of
- Electrodes of all types can be used,
- electrodes possibly needles with at least one electrode, or needle having one polarity and at
- At least one other electrode or needle preferably a plurality, having an opposite polarity similar
- electrode 138 is used to sense the electrical activity of the heart 128 and pace delivery of the electrical energy as disclosed in United States Patent 5,634,899, issued June 3, 1997, and
- the apparatus will first provide a signal to reduce the risk of creating an arrhythmia.
- the apparatus will first provide a signal to reduce the risk of creating an arrhythmia.
- the sensing lead 136 in coordination
- FIG. 4A-4B Another alternative embodiment of the electrical stimulation apparatus 10 shown in Figure 2 is shown in Figures 4A-4B.
- the apparatus 10" includes a bipolar
- proximal portion 112 having a proximal portion 112"and a distal portion 1 10".
- 112" has a depth guide 114" and the distal portion 1 10' has a shaft 102', an insulating material
- a delivery zone 106' a delivery zone 106', a distal tip 108', and a first electrode 103 that extends around the
- a second electrode 105 is spaced apart from the first
- electrode 103 and also extends around the circumference of the needle 101.
- the needle 101 is formed from a nonconductive material, such as a ceramic
- the first and second electrodes 103, 105 are electrically isolated from one another.
- a nonconductive material or substrate is positioned between the needle and the first and second electrodes.
- the electrodes and can be formed as
- Electrical leads B", A" provide electrical communication between the EFGU 117" and
- first and second electrodes 103 and 105 such that the first electrode 103 has an opposite
- one of the electrodes is an
- An alternative configuration (not shown) includes
- configurations include multiple needles. Furthermore, the polarity of the first and second
- electrodes 103 and 105 can be switched by programming the CPU 119" to switch the polarity
- the needle 100 is attached to a syringe 122 for injection of an agent or a cooling liquid and is then inserted into or proximal a
- the patch-type electrode 120 is attached to the surface of the delivery area.
- the bipolar needle 1.01 may also be used in a somewhat similar manner.
- a patch-type electrode 121 defines
- the patch-type electrode 121 is positioned against the surface of the skin at a site that is adjacent or over the target area of tissue. The caregiver
- the needle 100 then inserts the needle 100 through the opening 123 and into the target area of tissue until the depth guide 1 14 is against the surface of the skin. In this position, the needle 100 is not in
- the current in any of the alternate applications can have different waveforms
- a low level of current between about 0J mA and
- about 50 mA preferably between about 0.2mA and about 25mA, more preferably between about 0.4 mA and about 10mA, and more preferably between about 0.5 and about 5 mA is preferably conducted between the electrodes.
- the amplitude is between about 0.5 to 5 A although other current amplitudes can be
- the amplitude of the pulsed or alternating waveform In an embodiment that uses pulsed or alternating waveform, the amplitude of the pulsed or alternating waveform
- the amplitude of the signal is in the range
- the pulse width is in the range from about 0.1 ms to
- the treatment may generating pulses having a current
- a 5mA pulse can be delivered for 5 seconds in 5 second intervals for an extended period of 1
- 250 mA pulses can be delivered for 15 msec every second for one minute.
- 250 mA pulses can be delivered for 15 msec every second for one minute.
- the preferred apparatus allows for the delivery of constant voltages
- the distance in cm separating the respective electrodes preferably from about 5 V/cm to
- the pulses can be from about 1 V/cm to about
- 500V/cm preferably from about 10 V/cm to about 300 V/cm, more preferably about 50
- V/cm to about 100 V/cm.
- V/cm is generated by CVDD for 20 msec, at IHz for 1 minute.
- V/cm is generated for 1 msec at IHz for 1 to about 60 seconds.
- the needle 100 can be inserted
- the needle 100 is typically inserted
- electrode 120 depends on whether the procedure is used with minimally invasive techniques
- the patch-type electrode is place against the surface of
- the patient's body 150 such as the abdomen or thigh. If open heart surgery is performed, the
- patch-type electrode 120 can be placed near or against the surface of the myocardium.
- the bipolar needle 101 may also be used in this application in place of the needle 100.
- multiple needles could be inserted into the target
- needles could be configured to all have the same polarity.
- some of the needles have one polarity and the other needles have an opposite polarity to form a bipolar electrode configuration.
- Such a bipolar configuration may not
- One possible embodiment of a multiple needle device is
- the needle 100 is mounted on a first end of a first end of a first end of a first end of a second end of a first end of a first end of a second end of a first end of a second end of a first end of a second end of a first end of a second end of a first end of a second end of a first end of a second end of a first end of a second end of a first end of a needle 100 .
- trans-vascular catheter that can be introduced into a patient's vascular system and threaded to
- a trans-vascular catheter is used to introduce the
- the bipolar needle 101 also can be used with a trans-vascular catheter.
- the invention uses a second patch-type electrode 130 as the primary electrode.
- the second patch-type electrode 130 as the primary electrode.
- type electrode 130 which is for application proximal to or over the target area, has a delivery
- the size is adjustable, which allows for the entire target
- This adjustability also allows the size to be adjusted so that otherwise healthy tissue is not covered by the primary electrode 130, which
- FIG. 9A-9B Another possible embodiment of the needle 100"' is shown in Figures 9A-9B. In this
- an electrode support member 131 is connected to the needle 100'" adjacent to the insulating material 104 and projects outward therefrom.
- An electrode 133 is positioned
- the electrode 133 is spaced apart from the insulating
- the electrode 133 extends over
- the support member 131 can also be formed as a part of the insulating
- the needle 100'" is inserted into the myocardium until the electrode 133 is in contact with the surface of the myocardium.
- the current conducted between the needle 100'" and the electrode 133 can be controlled to a relatively discrete area.
- yet another possible embodiment includes a sensing lead
- a sensing electrode 138 that includes a sensing electrode 138 and a lead 140 that is preferably in electrical
- both the sensing lead In use, both the sensing lead
- the sensing lead 136 can be placed into electrical contact with any portion of the heart
- portions of the myocardium such as the epicardial surface, the myocardium that forms
- the sensing lead 136 is then used to sense the electrical impulses in the cardiac conduction system, which causes the heart to beat. In response to sensing these electrical
- heart is least susceptible to the inducement of arrhythmia during the refactory period.
- 118 paces the heart 128 if the heart beat is irregular. Such pacing is accomplished by sending
- Cardiac pacing is
- Choice of electric pulse amplitude, pulse width, pulse frequency, and number of pulses, is tailored to avoid stimulation of arrhythmia.
- V/cm or a constant current amplitude between about 5 mA to about 250 mA, with a frequency
- one possible treatment is in the range from about 1 pulse to about 60 pulses.
- any conductor in principal, any conductor,
- Electrode material such as metal or electrically conducting organic polymer (or combination of the two), can serve as the electrode material.
- Design of the electrode can take on a number of different
- the electrode(s) can consist of a straight pin, a screw, a helix, or a patch.
- patch can be further divided into mechanisms for delivery either to a smooth surface for
- Penetrating electrodes could be made
- strap type electrodes can be used with applications to target tissues such as bone, where it might be desired to wrap the electrode around the bone or other body tissue.
- Electrodes would be connected to a power source similar to
- the electrode systems or needles used with the present invention may be monopolor
- a mono electrode system has an electrode of one polarity positioned on one
- bipolar electrode electrodes of both polarities are mounted on a single structure such as a needle, catheter or probe and are electrically isolated from one another. Additionally, a single electrode may be used for each polarity or a group of electrodes might be used. For example,
- the electrodes may be either sacrificial or nonsacrificial. Examples of sacrificial materials
- silver/silver chloride include silver/silver chloride, copper, tin, nickel, iron, lithium, and amalgams thereof.
- nonsacrificial materials include platinum, gold, and other noble metals.
- electrodes also can be formed with zirconium, iridium, titanium, certain carbons, and stainless
- the return electrode may be in either direction as long as the circuit is closed.
- circuits diagrammed in Figures 11 A-l ID are circuits which are representative of
- the resistance RL is provided by the targeted body tissue.
- any of the previously described EFGUS 117 can be
- any appropriate CPU 1 19 can provide computer
- inventions can be used with an ex vivo process.
- cells such as muscle
- the process includes providing
- living cells preferably autologous living cells which have been removed form the prospective
- the living cells wherein the amplitude of the electrical field delivered to the targeted body tissue and the duration of the period of delivery is sufficient to cause the living to increase
- VEGF vascular endothelial growth factor
- KDR tyrosine kinase receptor
- This treatment can, under certain conditions, also cause cells to modulate their expression of
- FGFs acidic or basic fibroblast growth factors
- Figure 10 illustrates equipment for demonstrating in vitro cellular VEGF induced
- the bottom of the transwell is a microporous
- VEGF endothelial growth factor
- transwell system and then serum-starved for 24 hours. The cells are then placed into the
- the positive electrode is placed in the top well containing PBS and the cells.
- the positive electrode is placed in the
- VEGF as a chemoattractant
- BP blood pressure
- AS angiogenic scores
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU16203/00A AU1620300A (en) | 1998-11-12 | 1999-11-12 | Electrically mediated angiogenesis |
EP99958935A EP1128866A4 (en) | 1998-11-12 | 1999-11-12 | Electrically mediated angiogenesis |
US09/743,836 US6463323B1 (en) | 1998-11-12 | 1999-11-12 | Electrically mediated angiogenesis |
CA002339371A CA2339371C (en) | 1998-11-12 | 1999-11-12 | Electrically mediated angiogenesis |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19041298A | 1998-11-12 | 1998-11-12 | |
US19120998A | 1998-11-12 | 1998-11-12 | |
US10808098P | 1998-11-12 | 1998-11-12 | |
US09/191,209 | 1998-11-12 | ||
US09/190,412 | 1998-11-12 | ||
US60/108,080 | 1998-11-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000027466A1 true WO2000027466A1 (en) | 2000-05-18 |
Family
ID=27380410
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/026834 WO2000027466A1 (en) | 1998-11-12 | 1999-11-12 | Electrically mediated angiogenesis |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1128866A4 (en) |
AU (1) | AU1620300A (en) |
CA (1) | CA2339371C (en) |
WO (1) | WO2000027466A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002070065A2 (en) | 2001-03-05 | 2002-09-12 | Medtronic, Inc. | Stimulation for delivery of molecular therapy |
US6556872B2 (en) | 1999-08-24 | 2003-04-29 | Ev Vascular, Inc. | Therapeutic device and method for treating diseases of cardiac muscle |
US6560489B2 (en) | 1999-08-24 | 2003-05-06 | Em Vascular, Inc. | Therapeutic device and method for treating diseases of cardiac muscle |
WO2003089054A2 (en) * | 2002-04-16 | 2003-10-30 | Medtronic, Inc. | Electrical stimulation for thrombolytic therapy |
US6810286B2 (en) | 2000-03-06 | 2004-10-26 | Medtronic, Inc | Stimulation for delivery of molecular therapy |
WO2004050180A3 (en) * | 2002-11-30 | 2004-11-11 | Cardiac Pacemakers Inc | Method and apparatus for cell and electrical therapy of living tissue |
WO2006106132A1 (en) * | 2005-04-06 | 2006-10-12 | Friederike Scharmer | Electromedical implantable or extracorporeally applicable device for the treatment or monitoring of organs, and method for therapeutic organ treatment |
DE102008039712A1 (en) * | 2008-08-26 | 2010-03-04 | Ullrich Und Augst Gmbh | Method for regulation of biological process of human organisms on cellular plain by applying of electromagnetic field, comprises stimulating cells of biological organism with oscillation harmonious electro-magnetic oscillations |
CN107206230A (en) * | 2015-02-03 | 2017-09-26 | 罗琮柱 | The therapeutic system of blood vessel in skin |
US11185687B2 (en) | 2005-04-06 | 2021-11-30 | Berlin Heals Gmbh | Electromedical implantable or extracorporeally applicable device for the treatment or monitoring of organs, and methods for therapeutic organ treatment |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5433735A (en) | 1993-09-27 | 1995-07-18 | Zanakis; Michael F. | Electrical stimulation technique for tissue regeneration |
US5499971A (en) | 1990-06-15 | 1996-03-19 | Cortrak Medical, Inc. | Method for iontophoretically delivering drug adjacent to a heart |
US5634899A (en) | 1993-08-20 | 1997-06-03 | Cortrak Medical, Inc. | Simultaneous cardiac pacing and local drug delivery method |
US5855570A (en) * | 1995-04-12 | 1999-01-05 | Scherson; Daniel A. | Oxygen producing bandage |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5944710A (en) * | 1996-06-24 | 1999-08-31 | Genetronics, Inc. | Electroporation-mediated intravascular delivery |
-
1999
- 1999-11-12 AU AU16203/00A patent/AU1620300A/en not_active Abandoned
- 1999-11-12 CA CA002339371A patent/CA2339371C/en not_active Expired - Lifetime
- 1999-11-12 EP EP99958935A patent/EP1128866A4/en not_active Withdrawn
- 1999-11-12 WO PCT/US1999/026834 patent/WO2000027466A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5499971A (en) | 1990-06-15 | 1996-03-19 | Cortrak Medical, Inc. | Method for iontophoretically delivering drug adjacent to a heart |
US5634899A (en) | 1993-08-20 | 1997-06-03 | Cortrak Medical, Inc. | Simultaneous cardiac pacing and local drug delivery method |
US5433735A (en) | 1993-09-27 | 1995-07-18 | Zanakis; Michael F. | Electrical stimulation technique for tissue regeneration |
US5855570A (en) * | 1995-04-12 | 1999-01-05 | Scherson; Daniel A. | Oxygen producing bandage |
Non-Patent Citations (1)
Title |
---|
See also references of EP1128866A4 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6556872B2 (en) | 1999-08-24 | 2003-04-29 | Ev Vascular, Inc. | Therapeutic device and method for treating diseases of cardiac muscle |
US6560489B2 (en) | 1999-08-24 | 2003-05-06 | Em Vascular, Inc. | Therapeutic device and method for treating diseases of cardiac muscle |
US6810286B2 (en) | 2000-03-06 | 2004-10-26 | Medtronic, Inc | Stimulation for delivery of molecular therapy |
WO2002070065A3 (en) * | 2001-03-05 | 2002-11-21 | Medtronic Inc | Stimulation for delivery of molecular therapy |
WO2002070065A2 (en) | 2001-03-05 | 2002-09-12 | Medtronic, Inc. | Stimulation for delivery of molecular therapy |
WO2003089054A2 (en) * | 2002-04-16 | 2003-10-30 | Medtronic, Inc. | Electrical stimulation for thrombolytic therapy |
WO2003089054A3 (en) * | 2002-04-16 | 2004-03-18 | Medtronic Inc | Electrical stimulation for thrombolytic therapy |
WO2004050180A3 (en) * | 2002-11-30 | 2004-11-11 | Cardiac Pacemakers Inc | Method and apparatus for cell and electrical therapy of living tissue |
WO2006106132A1 (en) * | 2005-04-06 | 2006-10-12 | Friederike Scharmer | Electromedical implantable or extracorporeally applicable device for the treatment or monitoring of organs, and method for therapeutic organ treatment |
US9457184B2 (en) | 2005-04-06 | 2016-10-04 | Berlin Heals Holding Ag | Electromedical implantable or extracorporeally applicable device for the treatment or monitoring of organs, and method for therapeutic organ treatment |
US11185687B2 (en) | 2005-04-06 | 2021-11-30 | Berlin Heals Gmbh | Electromedical implantable or extracorporeally applicable device for the treatment or monitoring of organs, and methods for therapeutic organ treatment |
DE102008039712A1 (en) * | 2008-08-26 | 2010-03-04 | Ullrich Und Augst Gmbh | Method for regulation of biological process of human organisms on cellular plain by applying of electromagnetic field, comprises stimulating cells of biological organism with oscillation harmonious electro-magnetic oscillations |
CN107206230A (en) * | 2015-02-03 | 2017-09-26 | 罗琮柱 | The therapeutic system of blood vessel in skin |
EP3254725A4 (en) * | 2015-02-03 | 2018-07-18 | Jongju Na | Apparatus for treating blood vessels in skin |
CN107206230B (en) * | 2015-02-03 | 2021-07-27 | 维奥尔株式会社 | Device for treating blood vessels in the skin |
Also Published As
Publication number | Publication date |
---|---|
AU1620300A (en) | 2000-05-29 |
CA2339371A1 (en) | 2000-05-18 |
CA2339371C (en) | 2009-04-07 |
EP1128866A1 (en) | 2001-09-05 |
EP1128866A4 (en) | 2008-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6463323B1 (en) | Electrically mediated angiogenesis | |
US6738663B2 (en) | Implantable device and method for the electrical treatment of cancer | |
US6366808B1 (en) | Implantable device and method for the electrical treatment of cancer | |
US8014854B2 (en) | Method and device for treating abnormal tissue growth with electrical therapy | |
US8024048B2 (en) | Method and device for treating cancer with electrical therapy in conjunction with chemotherapeutic agents and radiation therapy | |
US7190997B1 (en) | Drug delivery device | |
US7742811B2 (en) | Implantable device and method for the electrical treatment of cancer | |
US7840278B1 (en) | Devices and methods for vagus nerve stimulation | |
US5634899A (en) | Simultaneous cardiac pacing and local drug delivery method | |
US7171263B2 (en) | Drug delivery device | |
JP5108787B2 (en) | A method for routing current to body tissue through embedded passive conductors | |
US8500713B2 (en) | Implantable electroporation therapy device and method for using same | |
US20050222646A1 (en) | Method and device for treating cancer with modified output electrical therapy | |
JP4302536B2 (en) | Electrical stimulation and thrombolysis treatment | |
US20030204161A1 (en) | Implantable electroporation therapy device and method for using same | |
WO2001000273A9 (en) | Devices and methods for vagus nerve stimulation | |
WO2000074773A1 (en) | Drug delivery device | |
WO1999004851A1 (en) | Iontophoretic delivery of an agent into cardiac tissue | |
CA2339371C (en) | Electrically mediated angiogenesis | |
WO1994000187A9 (en) | An implantable conducting system for the heart | |
WO1994000187A1 (en) | An implantable conducting system for the heart | |
EP2201980A1 (en) | Implantable tissue stimulator | |
Johnson | A critical review of the analgesic effects of TENS-like devices | |
US20230310871A1 (en) | Pulsed electric field ablation for implantable medical devices |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: AU Ref document number: 2000 16203 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2339371 Country of ref document: CA Ref country code: CA Ref document number: 2339371 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09743836 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999958935 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999958935 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |